{
    "organizations": [],
    "uuid": "95874110c6d13f4adabf5f7878a17d95d6ee585b",
    "author": "",
    "url": "https://www.reuters.com/article/brief-xencor-inc-expect-initial-data-fro/brief-xencor-inc-expect-initial-data-from-phase-2-trial-of-xmab5871-in-systemic-lupus-erythematosus-idUSFWN1P00S1",
    "ord_in_thread": 0,
    "title": "BRIEF-Xencor Inc - Expect Initial Data From Phase 2 Trial Of Xmab®5871 In Systemic Lupus Erythematosus",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "January 5, 2018 / 1:18 PM / Updated 5 minutes ago BRIEF-Xencor Inc - Expect Initial Data From Phase 2 Trial Of Xmab®5871 In Systemic Lupus Erythematosus Reuters Staff 1 Min Read \nJan 5 (Reuters) - Xencor Inc: \n* XENCOR INC - EXPECT INITIAL DATA FROM PHASE 2 TRIAL OF XMAB®5871 IN SYSTEMIC LUPUS ERYTHEMATOSUS \n* XENCOR INC - INITIATE PHASE 3 TRIAL IN SECOND HALF OF 2018 Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)",
    "published": "2018-01-05T15:18:00.000+02:00",
    "crawled": "2018-01-05T15:36:59.005+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "january",
        "pm",
        "updated",
        "minute",
        "ago",
        "inc",
        "expect",
        "initial",
        "data",
        "phase",
        "trial",
        "systemic",
        "lupus",
        "erythematosus",
        "reuters",
        "staff",
        "min",
        "read",
        "jan",
        "reuters",
        "xencor",
        "inc",
        "xencor",
        "inc",
        "expect",
        "initial",
        "data",
        "phase",
        "trial",
        "systemic",
        "lupus",
        "erythematosus",
        "xencor",
        "inc",
        "initiate",
        "phase",
        "trial",
        "second",
        "half",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}